FEATURES OF THERAPY WITH ANTIHISTAMINES IN PATIENTS WITH CHRONIC URTICARIA



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article is devoted to the role of the second generation antihistamines in the treatment of chronic urticaria. The features of the regimen for the use of the second generation antihistamines in this disease are highlighted. Particular attention is paid to the new representative of this group of drugs - bilastin. High efficacy and safety of the drug in patients with chronic urticaria is highlighted.

Full Text

Restricted Access

About the authors

O S Bodnya

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

Email: os.bodnya@yandex.ru
2/1, Barrikadnaia str., 125993, Moscow, Russia

N M Nenasheva

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

2/1, Barrikadnaia str., 125993, Moscow, Russia

References

  1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A et al. EAACI/GA2LEN/ EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009; 64: 1417-1426.
  2. Вeck L, Bernstein J, Maurer M. A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria. Acta Derm Venereol 2017; 97: 149-158.
  3. Дробик ОС, Воронова МЮ, Горячкина ЛА. Международные рекомендации по лечению хронической крапивницы - 2012. Что нового? Фарматека. 2013; (15): 49-53.
  4. Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017; 72: 2005-2016.
  5. Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review Allergy. 2012;.68: 90-96.
  6. Федеральные клинические рекомендации по диагностике и лечению крапивницы. РААКИ. 2015. [Federalnye klinicheskie rekomendacii po diagnostike i lecheniyu krapivnicy. RAAKI. 2015 (In Russ.)].
  7. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009; 39: 777-787.
  8. Kozel MM, Bossuyt PM, Mekkes JR, Bos JD. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol. 2003; 48: 409-416.
  9. Balp ММ, Vietri J, Tian H, Isherwood G et al. The Impact of Chronic Urticaria from the Patient’s Perspective: A Survey in Five European Countries. Patient. 2015; 8: 551-558.
  10. Леонова МВ, Дворников АС, Скрипкина ПА, Минкина ОВ, Гайдина ТА. Антигистаминные препараты в лечении хронической крапивницы. Обзор современных рекомендаций. Медицинский совет. 2016: (19): 48-57
  11. Jauregui I, Ferrer M, Montoro J, Davila I, Bartra J, del Cuvillo A et al. Antihista mines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007; 17: 41-52.
  12. Juhlin L. A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. Allergy. 1995; 50: 24-30.
  13. Kruszewski J, Klos K, Sulek K. Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 and 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine A randomized, double-blind, placebo controlled trial. Pol Merkur Lekarski. 2006; 21: 443-448.
  14. Klos K, Kruszewski J, Kruszewski R, Sulek K. The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow - a randomized, double-blind, placebo controlled trial. Pol Merkur Lekarski. 2006; 21: 449-453.
  15. Sanchez J, Zakzuk J, Cardona R. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine Induced Wheal. J Investig Allergol Clin Immunol. 2016; 26: 177-184.
  16. Sologuren A, Lucero ML, Valiente R, Valiente R, Charles H, Mair SJ. Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. 9th Congress of the European Association for Clinical Pharmacology and Therapeutics; July 12-15, 2009, Edinburgh, UK. Basic Clin Pharmacol Toxicol. 2009; 105: 106-107.
  17. Ferrer M, Sastre J, Jauregui I, Davila I, Montoro J, del Cuvillo A et al. Effect of antihistamine up-dosing in chronic urticaria. J Investig Allergol Clin Immunol. 2011; 21: 34-39.
  18. Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P et al. Bilastine International Working Group Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010; 65: 516-528.
  19. Sanchez-Borges M, Ansotegui I, Jimenez JM, Rojo MI, Serrano C, Yanez A. Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria. World Allergy Organ J. 2014; 7: 33.22.
  20. Инструкция по применению лекарственного препарата Никсар® (утв. Минздравом РФ 14.07.2016). [Instrukciya po primeneniyu lekarstvennogo preparata Niksar® (utv Minzdravom RF 14.07.2016).
  21. Church MK. Safety and efficacy of bilastine: a new H1-anti-histamine for the treatment of allergic rhinoconjunctivitis and urticarial. Expert Opin Drug Saf. 2011; 10: 779-793.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2017



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies